Latest Health News

KMD Brands reports strong sales momentum in the first five months of FY26, led by Kathmandu’s impressive growth in Australia and New Zealand, while EBITDA guidance signals a significant profit uplift.

Brightstar Resources has completed its strategic acquisition of Aurumin Limited, consolidating its Sandstone gold assets and boosting production by 12% in the December quarter. The company also advanced key feasibility studies, underpinning a promising growth trajectory.

MC Mining Limited reports strong progress on its Makhado steelmaking hard coking coal project with commissioning slated for March 2026, while Uitkomst Colliery struggles with declining production and rising costs.

Invion Limited has secured a $2 million non-dilutive grant from the South Korean government to advance preclinical studies for oesophageal cancer, expanded its global Photosoft technology license, and raised $1.3 million via convertible notes to strengthen its financial position.

Pure Foods Tasmania has reported a profitable quarter with improved margins and strategic growth moves, including a new contract packing deal and the acquisition of premium ice cream brand Elato.

Nuchev Limited reported a 19% decline in Q2 FY26 sales revenue, with steady retail performance in its Oli6® brand offset by a sharp drop in the Practitioner channel. The company remains debt-free and is advancing new product development to drive future growth.

DGR Global’s December quarter report highlights ongoing legal battles, a contested SolGold acquisition offer, and steady progress across its diverse resource portfolio.

Delorean Corporation has completed the $53 million Yarra Valley Water bioenergy facility and progressed key projects in South Australia and Victoria, supported by strong government grants and renewable gas policies.

Income Asset Management Group reveals a challenging Q2 FY2026 marked by a significant fraud event, resulting in losses and a strategic debt raise to shore up liquidity. Despite setbacks, client relationships remain intact as the group navigates legal and regulatory hurdles.

EVE Health Group has transitioned from development to commercial rollout, delivering first patient prescriptions of Dyspro™ and completing initial manufacturing of Libbo™, supported by a $1.1 million capital raise.

Hydrix Limited reported $2.3 million in revenue for Q2 FY26 and secured a $2.5 million initial contract with SynCardia Systems to develop a fully implantable artificial heart, setting a positive tone for 2026.

Admiralty Resources reported a $3.1 million cash outflow for the December quarter, with less than one quarter of funding available. Despite this, the company expects to maintain operations supported by iron ore sales and a significant prepayment.